chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Per dad, 2 hours after getting the vaccine the  patient  started laughing and crying inappropriately at the same time. This episode lasted around 4 hours. Patient then fell asleep and when she woke up she was fine. Patient has not had any problems or episodes since that day.
Pt developed red lesions with itching itching 24 hours after immunization, lesions started an ankles legs then both wrists and lower face.
Very sore lymph nodes under the arm; Patient received third dose; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received third booster dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2588) via an unspecified route of administration in the left arm on 04Oct2021 at 10:30 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included loratadine (CLARITINE) and ibuprofen (ADVIL) for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 12Mar2021 (at the age of 61-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA Vaccine; Lot Number: ER8733) via an unspecified route of administration in the left arm on 02Apr2021 (at the age of 62-years-old); as a single dose for COVID-19 immunisation. On 05Oct2021, the patient experienced very sore lymph nodes under the arm where the patient got the vaccine, especially on day2-3 and by day 4, most of the soreness dissipated. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event very sore lymph nodes under the arm was resolved on 07Oct2021.
Fever of 103.1 for more than 12 hours. Severe headache and lethargy, weakness, nausea for 2 days after 2nd vaccine.
Last year when I had my second dose on 4/15/2021 I had to go to Neurologist because high intense migraines and was diagnosed with central nervous vestibular dysfunction. I was later on referred to an ENT who diagnosed me with migraine associated vertigo (vestibular migraine) and prescribed me Verapamil. I had to go through vestibular rehabilitation therapy as I was suffering with dizziness and loss of balance.  In terms of OTC, I was taking (and still am along with verapamil) Tylenol, Advil and Dramamine. In terms of dietary supplements, the ENT made me take Coenzyme Q10, Magnesium Glycinate, Vitamin B2.  I am also taking vitamin C and D to help me with low energy. When I recently took the booster (/2/1/2022), I experienced the same sypmtoms, and had to go to the ENT to have my verapamil dose increased because I ahd even more migraines and was dealing with loss of balance again. To this day, I am still dealing with the side effects : migraines, imbalance, dizziness, I also developed anxiety disorder because of these side effects.
pain in her joints of both hands and both knees; Initial information received on 24-Jan-2020 regarding an unsolicited valid non-serious case received from a nurse.  This case involves a 52 years old female patient who experienced pain in her joints of both hands and both knees (arthralgia), while she received TYPHOID VI POLYSACCHARIDE VACCINE [TYPHIM VI].  Medical history, medical treatment, vaccination and family history were not provided.   On 09-Dec-2019, the patient received a 0.5 mL dose of suspect TYPHOID VI POLYSACCHARIDE VACCINE (lot R2A251M and expiry date: 11-May-2021) via an intramuscular route at an unknown administration site for prophylactic vaccination.  On 18_dec-2019, the patient developed a non-serious pain in her joints of both hands and both knees (arthralgia) 9 days following the administration of TYPHOID VI POLYSACCHARIDE VACCINE.  Other relevant tests were not reported.  Final diagnosis was arthralgia.   It was not reported if the patient received any corrective treatment.  On an unknown date, the patient had not recovered from the event.
Fever up to 103 degrees F lasting 5 days. Fever began a few hours after vaccine and has continued off and on 102-103 x 6 days.
pt had a hospital stay (name of facility not in med records) from 11/12 - 11/24/21 for generalized weakness and acute mental status changes; found to be positive for COVID on 11/18/21; MRI consistent of cystic progression, metastatic disease; treated with corticosteroids and ABX for UTI; dc'd to skilled nursing facility for rehab; poor oral intake; pt has fallen since been in rehab; increase in confusion; overall decline; pt was found unresponsive and passed away in the center
Vesicles on the face, chin, trunk, UE.  2 degree impetigo on the lesions on the face.
Patient went to discharge and on standing, felt lightheaded with leg & hand weakness.  She complained of chills and nausea and a sensation beginning from her upper arms/shoulders and spreading through to her torso and upper legs. It lasted about 5-10 seconds. She sat down immediately. She was always alert and coherent. Skin was warm and dry. Vital signs:  BP = 120/80, P=60, T=98.6, R=18 and regular. She stated she had not eaten breakfast and had only had a cup of coffee all morning. Her symptoms lasted a few minutes. She was given lunch to eat and felt better immediately. It was recommended she contact her doctor/clinic and she said she would do that.  She returned to her classroom at 12:15 pm. Follow-up call today (3/4/21) - she stated she had no more symptoms and was feeling well overall.
Narrative:  COPD exacerbation - antibiotic, guaifenesin and/or prednisone, DuoNeb - died hospice
Shortly after vaccination, pt experienced episode of "blacking out". She did not faint, but everything turned dark- she was light-headed, like she was going to pass out. This only lasted a couple of minutes and then she felt back to normal.
vitiligo on both arms, shoulders and back/white spots on both arms; This spontaneous case was reported by a consumer and describes the occurrence of VITILIGO (vitiligo on both arms, shoulders and back/white spots on both arms) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030A21A and 039K20A) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy, Analgesic effect (Codeine allergy), Blood pressure high and High cholesterol (High cholesterol). Concomitant products included LOSARTAN for Blood pressure high, ATORVASTATIN for High cholesterol.   On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In March 2021, the patient experienced VITILIGO (vitiligo on both arms, shoulders and back/white spots on both arms). At the time of the report, VITILIGO (vitiligo on both arms, shoulders and back/white spots on both arms) had not resolved.            No treatment information was provided by reporter.   Most recent FOLLOW-UP information incorporated above includes: On 08-Sep-2021: Added Patient demographics and pregnancy status, concomitant drug, relevant medical history updated. Added high blood pressure and High cholesterol as current condition. Added allergic condition that is allergy to penicillin and codeine.  Added losartan and Atorvastatin as concomitant medication.
Flu vaccine administered at work 10/10/18. Developed generalized urticaria w/o SOB. Has had flu vaccine in past.
Fever over 100 degrees, extreme muscular pain, lymph node swelling and pain in armpits and groin, slight joint pain, body aches
Nerve damage in arm and neck; This case was reported by a consumer via call center representative and described the occurrence of nerve damage in a 76-year-old patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine at an unknown dose. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced nerve damage. On an unknown date, the outcome of the nerve damage was unknown.   The reporter considered the nerve damage to be related to Shingles vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix and had nerve damage in my arm and neck.
Patient  age 16 was administered Janssen (J&J) vaccine on mobile unit.  Age limit for Janssen is 18.
No sure it is adverse however all people I know who got vaccine  no similar reaction Inflammation reddened area at injection site localized reaction Redness is beginning to subside
pt brought to hospital with c/o weakness, dizziness, SOB, productive cough; states was positive for COVID 1 month prior; experienced A Fib, bilateral pulmonary embolism, and fluid overload on chest xray; placed on BiPAP; pt's condition worsened and family transitioned pt to comfort care and dc'd all life-sustaining measures (BiPAP, antibiotics, IV fluids); pt died in the hospital
Redness, swelling and warm to touch to left arm. Oval rash noted 5x10cm to left deltoid. Mom was given strict ER precautions or to let us know if not better.
A spontaneous report has been received from a health professional. The report concerns a female patient of Native American ethnic origin (age 8 months). No medical history was reported. The following demography was reported for the patient's parent: Sex: Unknown No concomitant products were reported. The patient received Flumist Quadrivalent (influenza vaccine live reassort 4v) (batch number NH2013) (expiration date DEC-2021) once/single administration, via nasal route, on 10-NOV-2021. No malfunction has been reported for FLUMIST QUADRIVALENT. The report described a medication error for Flumist Quadrivalent. The reported term was medicated was given to patient under the age of 2 (Preferred term: Product administered to patient of inappropriate age). The outcome of the event was unknown. The event was considered non-serious. The reporter did not consider that there was a reasonable possibility of a causal relationship between Flumist Quadrivalent and the following event(s): medicated was given to patient under the age of 2. The company physician did not consider that there was a reasonable possibility of a causal relationship between Flumist Quadrivalent and the following event(s): medicated was given to patient under the age of 2. Device Information:  Combination Product Report: Yes Product As Reported: FLUMIST QUADRIVALENT Common Device Name: Nasal Spray Procode: CCQ  Product Role: Suspect.
A patient received an expired diluent part, no AE; Initial information regarding an unsolicited valid non-serious case was received from a nurse via Global Medical Information (GMI) (Reference number- 00574822) and transmitted to Sanofi on 23-Apr-2021  This case involves a patient (unknown demographics) who received an expired 0.5 mL dose of diluent part of HIB (PRP/T) VACCINE [ACT-HIB] (lot UJ144AAA and expiry date: 22-Mar-2021) via an unknown route in an unknown administration site for prophylactic vaccination on an unknown date (in between 22-Mar-2021 to 22-Apr-2021) (expired product administered).  The patient's medical history, past medical treatment(s), vaccination(s), concomitant medications and family history were not provided.   A Nurse seeking to know if ActHib would be valid if the diluent used was expired. The nurse was reporting a possible medication error occurred described as the ActHib was given after the expiration date of the diluent. The caller reported that at the time of this call the exact patients that received the vaccine are unknown due to being too early in the investigation.  This was a case of actual medication error case due to expired product administered (latency same day).  At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out by the regulatory authority . The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Pt received MMR, Hep A vaccines on 1/11/12. Developed diffuse erythema. Papular rash about 1 week later.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old male patient received BNT162b2 (BNT162B2 NOS), on 15Nov2022 at 10:00 as dose number unknown, single (Batch/Lot number: unknown) at the age of 70 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "diabetes" (unspecified if ongoing); "high blood pressure" (unspecified if ongoing). There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19 with Paxlovid treatment from 02Jul2023 to 06Jul2023. Clinical Course: Patient reported to have no known allergies.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300249023 Same patient, different product, different event (Paxlovid);
3rd dose in August 25, 2021 and given a 4th dose in October 11, 2021, Pt. given 4 doses in error.
(OMIC) Patient received Pneumovax at routine physical on 3/22/2006 about 11:30am. Complained of burning during injection. That afternoon worsening pain, redness and swelling. Seen in our walk in clinic that evening with 5+cm swollen, red, tender, indurated right deltoid. Treated with 80mg IM depo Medrol. Had swallowing difficulty 20-30 min after taking Cipro 3/23/2006. Went to ER treated for anaphylaxis with EPI, IV Benadryl, Solumedrol and Pepcid. Discharged on a Prednisone taper. Seen at 5:00 pm 3/24/06 at our walk in clinic by me to follow up on the arm reaction per the ER Drs orders. 2/3 of right arm was red with some swelling, no induration, + tenderness, bruise in mid deltoid.
ADACEL given on 9/7/2010. Had previously received at PCP on 7/23/09.
Severe left arm pain arthritis feeling on left 3 finger middle , ring and pinky. Deep ache in arm
Bell's Palsy, Fever, Fatigue, Headache, and Dizziness
Tiredness, nausea, sore arm. Feels like the flu. Severe headache.
Information has been received from a registered nurse concerning a patient thought to have been vaccinated with varicella virus vaccine live (Oka/Merck), on unspecified date. Four to six weeks  post vaccination the patient developed chickenpox. No further information was available. Additional information is not expected.
Red inflammation approximately 8cc diameter right below PNEUMOVAX injection site. No reaction at site of FLUVIRIN injection. Referred to MD, advised to use BENADRYL and ice packs by MD. Improving as of 9/26/09 with no increase and no pain.
PATIENT REPORTED FEELING A TINGLING SENSATION ON SKIN WITHIN 1 HOUR OF RECEIVING SHOT -- SENSATION MAY HAVE DEVELOPED TOWARD END OF ONSITE OBSERVATION PERIOD BUT PATIENT BELIEVED IT WAS GOOSEBUMPS FROM A/C. PATIENT REPORTED THAT OVER THE NEXT HOUR (BY APPROXIMATELY 12:30PM) SHE HAD FULL-BODY ITCHING INCLUDING TONGUE AND IMMEDIATELY WENT TO URGENT CARE. SHE WAS GIVEN A STEROID INJECTION AND SUPPLIED WITH DIPHENHYDRAMINE WHICH CONTROLLED HER REACTION. SHE HAS BEEN ADVISED THAT SHE NEEDS TO KEEP LIQUID DIPHENHYDRAMINE ON HAND AND WATCH FOR ANY RETURN OF SYMPTOMS OVER THE NEXT SEVERAL DAYS, AND IF SYMPTOMS RETURN TAKE BENADRYL IMMEDIATELY AND SEEK IMMEDIATE EMERGENT CARE.
ACUTE NON ST ELEVATION MI RESPIRATORY FAILURE, UNSPECIFIED ACUITY 2/18/2023  &   3/18/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Patient given Covid vaccine consent and he marked on it that he was on an immunosuppressive medication. He should have received a 3rd dose  Covid vaccine of 0.5ml, but while in the office he only received the booster dose of Moderna of 0.25ml. After the patient left office, doctor made me aware that the patient did not receive the correct dose. After speaking with the CMO of the company, he advised me to have the patient come back in to receive  an additional booster of 0.25ml of Moderna so he we have in total the correct amount for his immunosuppressed state of 0.5ml.  I called the patient and he came back into the office to receive his 2nd 0.25ml vaccine. Patient did not have an actual reaction, we had just given the incorrect dose initially, but now patient is fully vaccinated with 3rd dose of Moderna vaccine.
As soon as I received the injection my arm stiffened and it slowly crept up into my neck and other extremities within the next half hour seemingly tightening those muscles.  After a few days most muscle tightening stopped except at the injection site where there is still a softball size red,  warm to touch and stiff circle and is now 8 days after injection.  Some soarness still remains as well.  Periodically ice the area and take 500mg Tylenol.
A few hours after receiving vaccine, I began experiencing fever, nausea, chills. Then, within a couple more hours, abdominal pain increased substantially and I began vomiting. Unable to eat or keep water down, I tried to sleep to no avail. After more vomiting and worsening abdominal pain, I went to the ER around noon on April 15. I was given IV fluids, anti nausea meds, and pain meds. I was given a CT Scan and diagnosed with Appendicitis with a recommendation of laparoscopic surgery. I then went into surgery at 4pm and was sent home around 730-8pm to recover. I have had to miss a full week of work.
Welps on body and scalp; headache; body aches; fatigue; Itching along; This case was reported by a consumer via call center representative and described the occurrence of welts in a 83-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on an unknown date).   On 23rd September 2019, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On 25th September 2019, 2 days after receiving Shingrix, the patient experienced welts, headache, general body pain, fatigue and pruritus. On an unknown date, the outcome of the welts was recovering/resolving and the outcome of the headache, general body pain, fatigue and pruritus were unknown.   It was unknown if the reporter considered the welts, headache, general body pain, fatigue and pruritus to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix vaccine on left arm. The patient developed welts on her body and scalp and itching along with head and body aches and fatigue. The patient did not consent to follow up.
ACUTE STROKE DUE TO OCCLUSION OF RIGHT MIDDLE CEREBRAL ARTERY 5/3/2021 ACUTE STROKE DUE TO OCCLUSION OF RIGHT MIDDLE CEREBRAL ARTERY  ACUTE LACUNAR STROKE, UNSPECIFIED TYPE AND ARTERY 7/2/2021 ACUTE STROKE DUE TO OCCLUSION OF RIGHT MIDDLE CEREBRAL ARTERY  ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 5/3/2021 ACUTE STROKE DUE TO OCCLUSION OF RIGHT MIDDLE CEREBRAL ARTERY  HYPOTENSION 12/23/2021 ACUTE STROKE DUE TO OCCLUSION OF RIGHT MIDDLE CEREBRAL ARTERY  ACUTE STROKE DUE TO OCCLUSION OF RIGHT MIDDLE CEREBRAL ARTERY 5/3/2021 UTI (URINARY TRACT INFECTION)  ACUTE LACUNAR STROKE, UNSPECIFIED TYPE AND ARTERY 7/2/2021 UTI (URINARY TRACT INFECTION)  ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 5/3/2021 UTI (URINARY TRACT INFECTION)  HYPOTENSION 12/23/2021 UTI (URINARY TRACT INFECTION)  ACUTE STROKE DUE TO OCCLUSION OF RIGHT MIDDLE CEREBRAL ARTERY 5/3/2021 ATRIAL FIBRILLATION, UNSPECIFIED  ACUTE LACUNAR STROKE, UNSPECIFIED TYPE AND ARTERY 7/2/2021 ATRIAL FIBRILLATION, UNSPECIFIED  ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 5/3/2021 ATRIAL FIBRILLATION, UNSPECIFIED  HYPOTENSION 12/23/2021 ATRIAL FIBRILLATION, UNSPECIFIED  ACUTE STROKE DUE TO OCCLUSION OF RIGHT MIDDLE CEREBRAL ARTERY 5/3/2021 ATRIAL FIBRILLATION, UNSPECIFIED  ACUTE LACUNAR STROKE, UNSPECIFIED TYPE AND ARTERY 7/2/2021 ATRIAL FIBRILLATION, UNSPECIFIED  ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 5/3/2021 ATRIAL FIBRILLATION, UNSPECIFIED  HYPOTENSION 12/23/2021 ATRIAL FIBRILLATION, UNSPECIFIED
My armpit is swollen to the site of a softball causing some pain.; My armpit is swollen to the site of a softball causing some pain.; Dose received 3; This is a spontaneous report from a contactable reporter (consumer or other non-HCP). The reporter is the patient.   A 45-year-old male patient received bnt162b2 (BNT162B2), administered in left arm, administration date 16Dec2021 at 11:15 (Lot number: 33025BD) at the age of 45 years as dose 3 (booster), single for COVID-19 immunisation. The patient had no relevant medical history. Concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot Number: FN6207,Route of Administration: Unspecified, Anatomical Location: Left arm, Time of Administration: 18:30), administration date: 05Apr2021, when the patient was 44 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE, Lot Number: EW0151,Route of Administration: Unspecified, Anatomical Location: Left arm, Time of Administration: 18:30), administration date: 26Apr2021, when the patient was 44 years old, for COVID-19 immunisation.  The following information was reported: IMMUNISATION (non-serious) with onset 16Dec2021 at 11:15, outcome "unknown", described as "Dose received 3"; SWELLING (non-serious), AXILLARY PAIN (non-serious) all with onset 18Dec2021 at 12:00, outcome "not recovered", and all described as "My armpit is swollen to the site of a softball causing some pain". Therapeutic measures were not taken as a result of swelling and axillary pain.  Additional information: The patient had no known allergies. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.
Pt had Menactra ~1300 and went to school  3-4yrs later she felt weak, dizzy and had slight urticarial rash on face, upper chest and neck.  No wheezing. Cleared w/epinephrine, IV fluids.
Chills after 12 hours. Woke with headache, dizziness and burning up at 15 hours.  Last for 15 hours total then felt better.